跳至主要内容
临床试验/IRCT2016100630175N1
IRCT2016100630175N1已完成2 期

Study of oxymel caper product on metabolic syndrom diagnostic indexes in patients with diabetes type 2

Research and Technology Vice-Chancellory of Mashhad University of Medical Sciences0 个研究点目标入组 42 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
30 years 至 50 years(—)
性别
All

入选标准

  • Diabetic patients (type 2) whose disease has not been controlled inspit of taking complete oral medication based on ADA and they do not accept to take insulin? Ages between 30-65 years old? Definitive diagnosis of metabolic syndrom based on NECP:ATPIII diagnostic criteria
  • exclusion criteria:
  • Dissatisfaction with continuing participation? Necessity of any new therapeutic intervension during the study based on endocrinologist? Breast feeding and lactation? Complications such as increasing blood presure, chest pain, fatigue during treatment? Renal problem with increasing creatinine and decreasing GFR less than 60? Any systematic disease which influence on trend of disease such as cardiac diseases, liver problems and malignancies?Acute or sever complications of diabete such as DKA, hyperosmolar coma and sever hypoglycemia in recent 3 months? The critical illness which leads to hospitalisation in recent 3 months? Taking hyperglycemic agent such as immunosupressive and antileptic

排除标准

  • 未提供

研究者

发起方
Research and Technology Vice-Chancellory of Mashhad University of Medical Sciences

相似试验